IN-PERSON AND VIRTUAL
2021 American Society of Hematology Annual Meeting
December 11-14 , 2021 Atlanta , Georgia The 63rd ASH Annual Meeting and Exposition will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology .
2022 HIGHLIGHTS OF ASH ®
North America
January 7-8 , 2022 Seattle , Washington
January 14-15 , 2022 San Francisco , California • Washington , DC
January 21-22 , 2022 Chicago , Illinois • New York , New York
Check out online exclusives at www . ashclinicalnews . org
IN-PERSON
Tandem Meetings : Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
February 2-6 , 2022 Salt Lake City , Utah The combined annual meetings of the American Society for Transplantation and Cellular Therapy ( ASTCT ) and the Center for International Blood & Marrow Transplant Research ( CIB- MTR ) address the most timely issues in hematopoietic cell transplantation and cellular therapy .
IN-PERSON
66th Meeting of the Society of Thrombosis and Haemostasis Research
March 1-4 , 2022 Leipzig , Germany The GTH 2022 meeting will bring together nurses , students , and physicians to discuss a broad range of topics in thrombosis and hemostasis , including anticoagulation , women ’ s health , and complex hemostatic disorders .
IN-PERSON AND VIRTUAL
National Comprehensive Cancer Network Annual Congress
March 31 – April 2 , 2022 Orlando , Florida The National Comprehensive Cancer Network ( NCCN ) Annual Congress focuses on the practical management of patients with cancer , provides NCCN Guidelines updates , and includes other educational sessions on new treatments , therapies , and trends , and their application in patient care .
IN-PERSON
AACR Annual Meeting 2022
April 8-13 , 2022 New Orleans , Louisiana The annual meeting of the American Association for Cancer Research will explore the topics of cancer biology , survivorship , and global impact by bringing together researchers and clinicians from institutions around the world .
IN-PERSON AND VIRTUAL
Oncology Nursing Society Annual Congress
April 27 – May 1 , 2022 Anaheim , California The Oncology Nursing Society Congress will allow attendees to connect with oncology nursing colleagues from around the world to share cutting-edge treatment information , symptom management knowledge , and patient resources .
IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS
Hemorrhage : Fatal bleeding events have occurred in patients who received IMBRUVICA ® . Major hemorrhage ( ≥ Grade 3 , serious , or any central nervous system events ; e . g ., intracranial hemorrhage [ including subdural hematoma ], gastrointestinal bleeding , hematuria , and post procedural hemorrhage ) occurred in 4 % of patients , with fatalities occurring in 0.4 % of 2,838 patients who received IMBRUVICA ® in 27 clinical trials . Bleeding events of any grade including bruising and petechiae occurred in 39 %, and excluding bruising and petechiae occurred in 23 % of patients who received IMBRUVICA ® , respectively .
The mechanism for the bleeding events is not well understood .
Use of either anticoagulant or antiplatelet agents concomitantly with IMBRUVICA ® increases the risk of major hemorrhage . Across clinical trials , 3.1 % of 2,838 patients who received IMBRUVICA ® without antiplatelet or anticoagulant therapy experienced major hemorrhage . The addition of antiplatelet therapy with or without anticoagulant therapy increased this percentage to 4.4 %, and the addition of anticoagulant therapy with or without antiplatelet therapy increased this percentage to 6.1 %. Consider the risks and benefi ts of anticoagulant or antiplatelet therapy when co-administered with IMBRUVICA ® . Monitor for signs and symptoms of bleeding .
Consider the benefi t-risk of withholding IMBRUVICA ® for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding .
Infections : Fatal and non-fatal infections ( including bacterial , viral , or fungal ) have occurred with IMBRUVICA ® therapy . Grade 3 or greater infections occurred in 21 % of 1,476 patients who received IMBRUVICA ® in clinical trials . Cases of progressive multifocal leukoencephalopathy ( PML ) and Pneumocystis jirovecii pneumonia ( PJP ) have occurred in patients treated with IMBRUVICA ® . Consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections .
Monitor and evaluate patients for fever and infections and treat appropriately .
Cytopenias : In 645 patients with B-cell malignancies who received IMBRUVICA ® as a single agent , grade 3 or 4 neutropenia occurred in 23 % of patients , grade 3 or 4 thrombocytopenia in 8 % and grade 3 or 4 anemia in 3 %, based on laboratory measurements .
Monitor complete blood counts monthly .
Cardiac Arrhythmias and Cardiac Failure : Fatal and serious cardiac arrhythmias and cardiac failure have occurred with IMBRUVICA ® . Grade 3 or greater ventricular tachyarrhythmias occurred in 0.2 % of patients , Grade 3 or greater atrial fi brillation and atrial fl utter occurred in 4 %, and Grade 3 or greater cardiac failure occurred in 1 % of 1,476 patients who received IMBRUVICA ® in clinical trials . These events have occurred particularly in patients with cardiac risk factors , hypertension , acute infections , and a previous history of cardiac arrhythmias .
At baseline and then periodically , monitor patients clinically for cardiac arrhythmias and cardiac failure . Obtain an ECG for patients who develop arrhythmic symptoms ( e . g ., palpitations , lightheadedness , syncope , chest pain ) or new onset dyspnea . Manage cardiac arrhythmias and cardiac failure appropriately , and if it persists , consider the risks and benefi ts of IMBRUVICA ® treatment and follow dose modifi cation guidelines .
Hypertension : Hypertension occurred in 19 % of 1,476 patients who received IMBRUVICA ® in clinical trials . Grade 3 or greater hypertension occurred in 8 % of patients . Based on data from 1,124 of these patients , the median time to onset was 5.9 months ( range , 0.03 to 24 months ).
Monitor blood pressure in patients treated with IMBRUVICA ® and initiate or adjust anti-hypertensive medication throughout treatment with IMBRUVICA ® as appropriate .
2 ASH Clinical News